{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:00:48Z","timestamp":1783620048529,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ijmmb.2024.100528","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T05:43:07Z","timestamp":1705815787000},"page":"100528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral)"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4299-4317","authenticated-orcid":false,"given":"Sanjith","family":"Saseedharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratender Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Zirpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2436-4880","authenticated-orcid":false,"given":"Anirban Hom","family":"Choudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1974-2648","authenticated-orcid":false,"given":"Dip Narayan","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Sahasrabudhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Soni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4452-715X","authenticated-orcid":false,"given":"Sudhir","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Walse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agam Chandravadan","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwini","family":"Tayade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Bhadarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashesh","family":"Paliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan Kumar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant","family":"Nagvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Veeraraghavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijmmb.2024.100528_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious Gram-positive infections","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"10325","key":"10.1016\/j.ijmmb.2024.100528_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijmmb.2024.100528_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.ijmmb.2024.100528_bib4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/S1473-3099(14)70780-7","article-title":"Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data","volume":"14","author":"Van Boeckel","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijmmb.2024.100528_bib5","series-title":"Surveillance Network","author":"ICMR","year":"2021"},{"issue":"12","key":"10.1016\/j.ijmmb.2024.100528_bib6","doi-asserted-by":"crossref","first-page":"e1262","DOI":"10.1016\/S2214-109X(18)30448-0","article-title":"India's escalating burden of non-communicable diseases","volume":"6","author":"Arokiasamy","year":"2018","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.ijmmb.2024.100528_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/20503121221095485","article-title":"Systematic review and meta-analysis of comorbidities and associated risk factors in Indian patients of community-acquired pneumonia","volume":"10","author":"Ghia","year":"2022","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.ijmmb.2024.100528_bib8","article-title":"Meeting the unmet need in the management of MDR gram-positive infections with oral bactericidal agent levonadifloxacin","volume":"2022","author":"Mehta","year":"2022","journal-title":"Crit Care Res Pract"},{"issue":"1","key":"10.1016\/j.ijmmb.2024.100528_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jac\/dkp377","article-title":"Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?","volume":"65","author":"Nguyen","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijmmb.2024.100528_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s40121-021-00557-w","article-title":"Impact of underlying comorbidities on outcomes of patients treated with ceftaroline fosamil for complicated skin and soft tissue infections: pooled results from three Phase III randomized clinical trials","volume":"11","author":"Wilcox","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"6","key":"10.1016\/j.ijmmb.2024.100528_bib11","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"issue":"9","key":"10.1016\/j.ijmmb.2024.100528_bib12","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciy724","article-title":"Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal \u03b2-lactams with vancomycin","volume":"68","author":"Schreier","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.ijmmb.2024.100528_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227009","article-title":"Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: a first report from South India","volume":"14","author":"Bakthavatchalam","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ijmmb.2024.100528_bib14","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/jac\/dkx289","article-title":"Pharmacodynamics of teicoplanin against MRSA","volume":"72","author":"Ramos-Mart\u00edn","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.ijmmb.2024.100528_bib15","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s10096-013-1867-z","article-title":"Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials","volume":"32","author":"Jiang","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.ijmmb.2024.100528_bib16","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1038\/s41598-022-13874-y","article-title":"Renal replacement therapy and concurrent fluconazole therapy increase linezolid-related thrombocytopenia among adult patients","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.ijmmb.2024.100528_bib17","doi-asserted-by":"crossref","first-page":"e00605","DOI":"10.1128\/AAC.00605-19","article-title":"Reappraisal of linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ijmmb.2024.100528_bib18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/jac\/dku513","article-title":"Comment on: efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials","volume":"70","author":"Potashman","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.ijmmb.2024.100528_bib19","first-page":"30","article-title":"Efficacy and safety of a novel broad-spectrum anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a Phase 3, open label, randomized study","volume":"68","author":"Bhatia","year":"2020","journal-title":"J Assoc Phys India"},{"key":"10.1016\/j.ijmmb.2024.100528_bib20","author":"EMROK & EMROK O [Internet]"},{"issue":"3","key":"10.1016\/j.ijmmb.2024.100528_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/ebnurs-2020-103303","article-title":"What are Delphi studies?","volume":"23","author":"Barrett","year":"2020","journal-title":"Evid Base Nurs"},{"issue":"7","key":"10.1016\/j.ijmmb.2024.100528_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1469-0691.2001.00059.x","article-title":"Limitations of presently available glycopeptides in the treatment of Gram-positive infection","author":"Ziglam","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.ijmmb.2024.100528_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02297-17","article-title":"Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2024.100528_bib24","series-title":"Wockhardt limited","year":"2020"},{"issue":"1","key":"10.1016\/j.ijmmb.2024.100528_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/ijabmr.ijabmr_602_21","article-title":"Prescription-event monitoring study on safety and efficacy of levonadifloxacin (oral and I.V.) in management of bacterial infections: findings of real-world observational study","volume":"12","author":"Mehta","year":"2022","journal-title":"Int J Appl Basic Med Res"},{"issue":"4","key":"10.1016\/j.ijmmb.2024.100528_bib26","article-title":"Real-world evidence of efficacy and safety of levonadifloxacin (oral and IV) in the management of acute bacterial skin and skin structure infections (ABSSSI): findings of a retrospective, multi-center study","volume":"14","author":"Mehta","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ijmmb.2024.100528_bib27","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence","volume":"13","author":"Bhagwat","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"10.1016\/j.ijmmb.2024.100528_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.18773\/austprescr.2020.008","article-title":"Oral or intravenous antibiotics?","volume":"43","author":"McCarthy","year":"2020","journal-title":"Aust Prescr"},{"key":"10.1016\/j.ijmmb.2024.100528_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijid.2015.09.023","article-title":"Diabetic foot infections: what have we learned in the last 30 years?","volume":"40","author":"U\u00e7kay","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijmmb.2024.100528_bib30","doi-asserted-by":"crossref","first-page":"56","DOI":"10.18203\/2349-3933.ijam20214882","article-title":"Methicillin resistant Staphylococcus aureus-importance of appropriate empirical therapy in serious infections","volume":"9","author":"Reddy","year":"2022","journal-title":"Int J Adv Med"},{"key":"10.1016\/j.ijmmb.2024.100528_bib31","author":"US Food and Drug"},{"key":"10.1016\/j.ijmmb.2024.100528_bib32","doi-asserted-by":"crossref","first-page":"919","DOI":"10.23958\/ijirms\/vol06-i12\/1295","article-title":"Efficacy and Safety of Levonadifloxacin in the Management of Community-Acquired Bacterial Pneumonia (CABP): Findings of a Retrospective, Real-World, Multi-Centre Study","volume":"6","author":"Prabhudesai","year":"2021","journal-title":"ijirms"},{"issue":"10","key":"10.1016\/j.ijmmb.2024.100528_bib33","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.18203\/2320-6012.ijrms20213685","article-title":"Efficacy and safety of intravenous and\/or oral levonadifloxacin in the management of secondary bacterial pulmonary infections in COVID-19 patients: findings of a retrospective, real-world, multi-center study","volume":"9","author":"Saseedharan","year":"2021","journal-title":"Int J Res Med Sci"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085724000033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0255085724000033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:21:25Z","timestamp":1759346485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0255085724000033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":33,"alternative-id":["S0255085724000033"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100528","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment challenges in the management of difficult-to-treat gram-positive infections: A consensus view apropos therapeutic role of novel anti-MRSA antibiotics, levonadifloxacin (IV) and alalevonadifloxacin (oral)","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2024.100528","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100528"}}